glp-1 side effects and risks Exploring the of Receptor Agonist: To Ensure Its Optimal Positioning May 4, 2025: New study

How Weight-Loss Drugs Escaped the Diabetes Clinic GLP-1 receptor agonists were developed and approved for type 2 diabetes, with obesity approval following only after trials like STEP and SURMOUNT showed consistent, significant weight loss details we cover in Part 1 on how these drugs work

Humphries F, Shmuel-Galia L, Ketelut-Carneiro N, Li S, Wang B, Nemmara VV, et al

Pathophysiology of diabetic kidney disease and therapeutic targets of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists

This article summarizes the receptor pharmacology, structural properties, and published study landscape for tirzepatide vs retatrutide , and outlines considerations for researchers selecting between them for protocol design